Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer Mon, 20 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Matt Abernethy is joining the executive management team as Chief Financial Officer (CFO). "We are very pleased to welcome Matt Abernethy to the Neurocrine team as our Chief Financial Officer," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. Abernethy has nearly 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry. He joins Neurocrine from Zimmer Biomet, where he held various positions over the past nine years including Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines.
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry Tue, 14 Nov 2017 18:34:00 +0000 SAN DIEGO, Nov. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) were published in the Journal of Clinical Psychiatry1. The once-daily 80 mg and 40 mg doses of INGREZZA continued to maintain symptom improvement and were generally well-tolerated over long-term dosing in patients with TD, a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. "We are pleased with the long-term data, which demonstrate the ability of INGREZZA to effectively improve the symptoms of tardive dyskinesia with durable response," said Christopher O'Brien, M.D., Chief Medical Officer of Neurocrine Biosciences.
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association Thu, 09 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that INGREZZA® (valbenazine) capsules, the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, was awarded the 2017 Pantheon DiNA Award for Outstanding Therapeutic Product by the California Life Sciences Association (CLSA). CLSA is the state's largest and most influential life sciences advocacy and business leadership organization. CLSA will honor this year's winners at the 2017 Pantheon DiNA Awards ceremony on Friday, November 10, at the Marriott Marquis in San Francisco.
Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress Tue, 07 Nov 2017 21:01:00 +0000 SAN DIEGO, Nov. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that data for INGREZZA® (valbenazine) capsules, the first FDA approved treatment for adults with tardive dyskinesia (TD), will be presented at the 2017 Neuroscience Education Institute Congress to be held November 8-12 in Colorado Springs, Colorado. Data being presented include analyses from the RE-KINECT study, a real-world screening study and registry that describes the presence and impact of involuntary movements in patients taking antipsychotics, as well as pooled data analyses from INGREZZA clinical studies across patient sub-groups. "We are pleased to share findings on the impact of tardive dyskinesia, which is characterized by uncontrollable, abnormal and repetitive movements, on real-world patients," said Chris O'Brien, M
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.43 (median winner: 1.53)
Instit. Ownership: 0% (median winner: 63%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.